Clinically, the elevation of CD4+CD25+FOXP3+ Tregs in the peripheral blood has been found to be associated with a higher risk of tumor recurrence and a poor prognosis in breast cancer patients [34]. This evidence concerns the gene CD4 and breast carcinoma.